CD274 and invasive breast carcinoma: According to a retrospective study that enrolled 1091 patients with invasive breast cancer, 27.0% of patients (295/1091) were PD-L1 high, and 73.0% of patients (796/1091) were PD-L1 low (the mean immunoscore for PD-L1 was used as the cut-off)17.